Skip to main content
SpringerLink
Log in

Natural Products for Promoting Joint Health and Managing Osteoarthritis

  • Complementary and Alternative Medicine (S Kolasinski, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Osteoarthritis, the most common joint disease, is associated with substantial medical costs, lost productivity, and reduced quality of life. However, available pharmaceutical treatments have limitations in terms of efficacy and long-term safety.

Recent Findings

In vitro evidence suggests that some natural products may possess anti-inflammatory and anti-oxidative properties and may inhibit the release of key osteoarthritis-related cytokines. There is, therefore, ongoing interest in identifying natural products that safely promote joint health and treat osteoarthritis. Numerous plant extracts, including curcumin, Boswellia extract, and pycnogenol, have shown effect sizes (ES) for reducing pain and functional disability larger than those observed with analgesics and products such as glucosamine and chondroitin. The ES for methylsulfonylmethane and avocado/soybean unsaponifiables are also considered to be clinically relevant.

Summary

Data from a small number of studies using natural products for treating osteoarthritis are promising but require confirmation in further well-designed clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin N Am. 2013;39:1–19.

    Article  Google Scholar 

  2. Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017;114:9332–6.

    Article  CAS  Google Scholar 

  3. Nguyen US, Zhang Y, Zhu Y, Niu J, Zhang B, Felson DT. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med. 2011;155:725–32.

    Article  Google Scholar 

  4. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–30.

    Article  Google Scholar 

  5. Hermans J, Koopmanschap MA, Bierma-Zeinstra SM, van Linge JH, Verhaar JA, Reijman M, et al. Productivity costs and medical costs among working patients with knee osteoarthritis. Arthritis Care Res (Hoboken). 2012;64:853–61.

    Article  Google Scholar 

  6. London NJ, Miller LE, Block JE. Clinical and economic consequences of the treatment gap in knee osteoarthritis management. Med Hypotheses. 2011;76:887–92.

    Article  Google Scholar 

  7. Rahmati M, Nalesso G, Mobasheri A, Mozafari M. Aging and osteoarthritis: central role of the extracellular matrix. Ageing Res Rev. 2017;40:20–30.

    Article  CAS  Google Scholar 

  8. Mobasheri A, Matta C, Zakany R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80:237–44.

    Article  CAS  Google Scholar 

  9. Henrotin YE, Deberg MA, Crielaard JM, Piccardi N, Msika P, Sanchez C. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol. 2006;33:1668–78.

    PubMed  Google Scholar 

  10. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003;33:155–67.

    Article  CAS  Google Scholar 

  11. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review of management. Br Med Bull. 2008;87:77–95.

    Article  Google Scholar 

  12. Hunter DJ, Guermazi A, Roemer F, Zhang Y, Neogi T. Structural correlates of pain in joints with osteoarthritis. Osteoarthr Cartil. 2013;21:1170–8.

    Article  CAS  Google Scholar 

  13. Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, et al. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the in vitro osteoclast differentiation in arthritis study. Arthritis Rheum. 2013;65:148–58.

    Article  CAS  Google Scholar 

  14. Clarkin C, Olsen BR. On bone-forming cells and blood vessels in bone development. Cell Metab. 2010;12:314–6.

    Article  CAS  Google Scholar 

  15. Hunter DJ, McDougall JJ, Keefe FJ. The symptoms of osteoarthritis and the genesis of pain. Rheum Dis Clin N Am. 2008;34:623–43.

    Article  Google Scholar 

  16. Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B, Stanaitis I, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. 2014;9:e91286.

    Article  Google Scholar 

  17. Wang H, Cheng Y, Shao D, Chen J, Sang Y, Gui T, et al. Metabolic syndrome increases the risk for knee osteoarthritis: a meta-analysis. Evid Based Complement Alternat Med. 2016;2016:7242478.

    PubMed  PubMed Central  Google Scholar 

  18. Mobasheri A, Rayman MP, Gualillo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2017;13:302–11.

    Article  CAS  Google Scholar 

  19. Courties A, Sellam J, Maheu E, Cadet C, Barthe Y, Carrat F, et al. Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. RMD Open. 2017;3:e000344.

    Article  Google Scholar 

  20. Eymard F, Parsons C, Edwards MH, Petit-Dop F, Reginster JY, Bruyere O, et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthr Cartil. 2015;23:851–9.

    Article  CAS  Google Scholar 

  21. Li H, George DM, Jaarsma RL, Mao X. Metabolic syndrome and components exacerbate osteoarthritis symptoms of pain, depression and reduced knee function. Ann Transl Med. 2016;4:133.

    Article  CAS  Google Scholar 

  22. Salamon L, Morovic-Vergles J, Marasovic-Krstulovic D, Kehler T, Sakic D, Badovinac O, et al. Differences in the prevalence and characteristics of metabolic syndrome in rheumatoid arthritis and osteoarthritis: a multicentric study. Rheumatol Int. 2015;35:2047–57.

    Article  CAS  Google Scholar 

  23. King KB, Rosenthal AK. The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms. Osteoarthr Cartil. 2015;23:841–50.

    Article  CAS  Google Scholar 

  24. Medina-Luna D, Santamaria-Olmedo MG, Zamudio-Cuevas Y, Martinez-Flores K, Fernandez-Torres J, Martinez-Nava GA, et al. Hyperlipidemic microenvironment conditionates damage mechanisms in human chondrocytes by oxidative stress. Lipids Health Dis. 2017;16:114.

    Article  Google Scholar 

  25. Sun AR, Panchal SK, Friis T, Sekar S, Crawford R, Brown L, et al. Obesity-associated metabolic syndrome spontaneously induces infiltration of pro-inflammatory macrophage in synovium and promotes osteoarthritis. PLoS One. 2017;12:e0183693.

    Article  Google Scholar 

  26. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthr Cartil. 2015;23:1955–65.

    Article  CAS  Google Scholar 

  27. Thomas S, Browne H, Mobasheri A, Rayman MP. What is the evidence for a role for diet and nutrition in osteoarthritis? Rheumatology. 2018;57(suppl 4):iv61–74.

    Article  Google Scholar 

  28. Liu X, Eyles J, McLachlan AJ, Mobasheri A. Which supplements can I recommend to my osteoarthritis patients? Rheumatology (Oxford). 2018;57(suppl 4):iv75–87.

    Article  Google Scholar 

  29. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167–75.

    Article  Google Scholar 

  30. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–88.

    Article  CAS  Google Scholar 

  31. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465–74.

    Article  CAS  Google Scholar 

  32. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55.

    Article  CAS  Google Scholar 

  33. Osteoarthritis 2018. https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Osteoarthritis. Accessed 10 Jan 2018.

  34. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Juni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390:e21–33.

    Article  Google Scholar 

  35. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162:46–54.

    Article  Google Scholar 

  36. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225.

    Article  Google Scholar 

  37. Acetaminophen overdose and liver injury—background and options for reducing injury 2009 https://www.fda.gov/ohrms/dockets/AC/09/briefing/2009-4429b1-01-FDA.pdf. Accessed 22 Mar 2018.

  38. Paracetamol 2016 https://www.nhs.uk/conditions/paracetamol/. Accessed 8 Jan 2018.

  39. Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016;4:CD007400.

    PubMed  Google Scholar 

  40. da Costa BR, Hari R, Juni P. Intra-articular corticosteroids for osteoarthritis of the knee. JAMA. 2016;316:2671–2.

    Article  Google Scholar 

  41. Rutjes AW, Juni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180–91.

    Article  Google Scholar 

  42. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis?—a narrative review from the lessons taken with five products. Osteoarthr Cartil. 2011;19:1–21.

    Article  CAS  Google Scholar 

  43. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 2016;17:1192–202.

    PubMed  Google Scholar 

  44. Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, et al. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem. 2012;23:1367–77.

    Article  CAS  Google Scholar 

  45. Committee for Medicinal Products for Human Use. Guideline on clinical investigation on medicinal products used in the treatment of osteoarthritis 2010 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003440.pdf. Accessed 22 Mar 2018.

  46. Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage. 2015;6:30–44.

    Article  Google Scholar 

  47. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007;96:3168–80.

    Article  CAS  Google Scholar 

  48. Betz JM, Brown PN, Roman MC. Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia. 2011;82:44–52.

    Article  CAS  Google Scholar 

  49. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012;14:201.

    Article  CAS  Google Scholar 

  50. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30:357–63.

    Article  CAS  Google Scholar 

  51. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005:CD002946.

  52. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012;4:167–80.

    Article  CAS  Google Scholar 

  53. Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66:1844–55.

    Article  Google Scholar 

  54. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014;78:184–7.

    Article  CAS  Google Scholar 

  55. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1:CD005614.

    PubMed  PubMed Central  Google Scholar 

  56. Martel-Pelletier J, Kwan Tat S, Pelletier JP. Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review. Osteoarthr Cartil. 2010;18(Suppl 1):S7–11.

    Article  Google Scholar 

  57. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163:1514–22.

    Article  CAS  Google Scholar 

  58. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.

    Article  Google Scholar 

  59. Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997;64:825–34.

    CAS  PubMed  Google Scholar 

  60. Maheu E, Mazieres B, Valat JP, Loyau G, Le Loet X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41:81–91.

    Article  CAS  Google Scholar 

  61. Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol. 2001;30:242–7.

    Article  CAS  Google Scholar 

  62. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 2002;47:50–8.

    Article  CAS  Google Scholar 

  63. Butawan M, Benjamin RL, Bloomer RJ. Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. Nutrients. 2017 16;9(3). https://doi.org/10.3390/nu9030290.

    Article  Google Scholar 

  64. van der Merwe M, Bloomer RJ. The influence of methylsulfonylmethane on inflammation-associated cytokine release before and following strenuous exercise. J Sports Med (Hindawi Publ Corp). 2016;2016:7498359.

    Google Scholar 

  65. Ezaki J, Hashimoto M, Hosokawa Y, Ishimi Y. Assessment of safety and efficacy of methylsulfonylmethane on bone and knee joints in osteoarthritis animal model. J Bone Miner Metab. 2013;31:16–25.

    Article  CAS  Google Scholar 

  66. Brien S, Prescott P, Lewith G. Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med. 2011;2011:528403.

    PubMed  PubMed Central  Google Scholar 

  67. Sharma S, Sahu D, Das HR, Sharma D. Amelioration of collagen-induced arthritis by Salix nigra bark extract via suppression of pro-inflammatory cytokines and oxidative stress. Food Chem Toxicol. 2011;49:3395–406.

    Article  CAS  Google Scholar 

  68. Vlachojannis JE, Cameron M, Chrubasik S. A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytother Res. 2009;23:897–900.

    Article  CAS  Google Scholar 

  69. Nahrstedt A, Schmidt M, Jaggi R, Metz J, Khayyal MT. Willow bark extract: the contribution of polyphenols to the overall effect. Wien Med Wochenschr. 2007;157:348–51.

    Article  Google Scholar 

  70. Vlachojannis J, Magora F, Chrubasik S. Willow species and aspirin: different mechanism of actions. Phytother Res. 2011;25:1102–4.

    Article  CAS  Google Scholar 

  71. Fiebich BL, Chrubasik S. Effects of an ethanolic Salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004;11:135–8.

    Article  CAS  Google Scholar 

  72. Bonaterra GA, Heinrich EU, Kelber O, Weiser D, Metz J, Kinscherf R. Anti-inflammatory effects of the willow bark extract STW 33-I (Proaktiv((R))) in LPS-activated human monocytes and differentiated macrophages. Phytomedicine. 2010;17:1106–13.

    Article  CAS  Google Scholar 

  73. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthr Cartil. 2010;18:141–9.

    Article  CAS  Google Scholar 

  74. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58:899–908.

    Article  CAS  Google Scholar 

  75. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19:717–29.

    Article  CAS  Google Scholar 

  76. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50:349–69.

    Article  CAS  Google Scholar 

  77. Sengupta K, Kolla JN, Krishnaraju AV, Yalamanchili N, Rao CV, Golakoti T, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011;354:189–97.

    Article  CAS  Google Scholar 

  78. Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage. Phytother Res. 2010;24:905–12.

    PubMed  Google Scholar 

  79. Prabhavathi K, Chandra US, Soanker R, Rani PU. A randomized, double blind, placebo controlled, cross over study to evaluate the analgesic activity of Boswellia serrata in healthy volunteers using mechanical pain model. Indian J Pharm. 2014;46:475–9.

    Article  CAS  Google Scholar 

  80. Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). 2006;3:1.

    Article  Google Scholar 

  81. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep. 2008;13:271–6.

    Article  CAS  Google Scholar 

  82. Marini A, Grether-Beck S, Jaenicke T, Weber M, Burki C, Formann P, et al. Pycnogenol(R) effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women. Skin Pharmacol Physiol. 2012;25:86–92.

    Article  CAS  Google Scholar 

  83. Mulek M, Seefried L, Genest F, Hogger P. Distribution of constituents and metabolites of maritime pine bark extract (Pycnogenol(R)) into serum, blood cells, and synovial fluid of patients with severe osteoarthritis: a randomized controlled trial. Nutrients. 2017;9.

    Article  Google Scholar 

  84. Schoonees A, Visser J, Musekiwa A, Volmink J. Pycnogenol(R) (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database Syst Rev. 2012:CD008294.

  85. Bartels EM, Bliddal H, Schondorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil. 2010;18:289–96.

    Article  CAS  Google Scholar 

  86. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014:CD005117.

  87. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006;166:1899–906.

    Article  CAS  Google Scholar 

  88. Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33:75–85.

    Article  CAS  Google Scholar 

  89. Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel. 2013;5:219–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. LeDoux MA, Appelhans KR, Braun LA, Dziedziczak D, Jennings S, Liu L, et al. A quality dietary supplement: before you start and after it's marketed—a conference report. Eur J Nutr. 2015;54(Suppl 1):S1–8.

    Article  Google Scholar 

Download references

Funding

Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, and was funded by Pfizer.

Author information

Authors and Affiliations

  1. Physical Therapy and Rehabilitation Department, Institute of Pathology, Bone and Cartilage Research Center, University of Liège, Place du 20 Août 7, 4000, Arthropôle, Liège, Belgium

    Yves Henrotin

  2. Princess Paola Hospital, Marche-en-Famenne, Belgium

    Yves Henrotin

  3. Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania

    Ali Mobasheri

  4. Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen’s Medical Centre, Nottingham, UK

    Ali Mobasheri

  5. School of Veterinary Medicine, University of Surrey, Guildford, Surrey, UK

    Ali Mobasheri

Authors
  1. Yves Henrotin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Mobasheri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves Henrotin.

Ethics declarations

Conflict of Interest

YH is the founder of Artialis SA, a spin-off company of the University of Liège. He has also received fees from Bepharbel, Expansciences, Flexion, GSK, Ibsa, KiOmed Pharma SA (formerly Synolyne Pharma SA), Labhra, Nestle, and Tilman SA.

AM has consulted for Pfizer Consumer Healthcare, but he does not have any conflicts of interest to declare in relation to this work. AM has received grant support from Arthritis Research UK, European Commission (FP7, IMI, Marie Skłodowska-Curie), Mars (Waltham Centre for Pet Nutrition), and Merck; consultancy fees from AbbVie, AlphaSights, Galapagos and Servier, Pfizer Consumer Healthcare, and Science Branding Communications; and speaker fees from American College of Rheumatology, Bioiberica SA, Korean Society for Osteoarthritis and Cartilage Repair, and Spanish Society of Rheumatology.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Complementary and Alternative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henrotin, Y., Mobasheri, A. Natural Products for Promoting Joint Health and Managing Osteoarthritis. Curr Rheumatol Rep 20, 72 (2018). https://doi.org/10.1007/s11926-018-0782-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-018-0782-9

Keywords

Search

Navigation